AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

INSL3 as a Biomarker of Pubertal Activation: Role in Evaluating Precocious and Delayed Puberty

Recruitingn/aAges 0 Years - 18 YearsAllIRCCS Azienda Ospedaliero-Universitaria di Bologna
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is an observational study in children up to 16 years old who are suspected of having central precocious puberty or delayed puberty. The main questions it aims to answer are: * Can the level of insulin-like peptide 3 (INSL3) predict if a child's puberty has truly started? * Can this marker help reduce the need for more complex and invasive tests? Participants will: * Give one extra blood sample just before starting the standard gonadotropin-releasing hormone (GnRH) stimulation test (during the baseline blood draw). * Have this extra sample used to measure the INSL3 hormone. * Complete the rest of the GnRH test as prescribed by their doctor. Researchers will compare the INSL3 hormone levels in children who have a positive GnRH test to those who have a negative test. This will help researchers learn if INSL3 can be used as a new, simple tool to diagnose early or delayed puberty.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age between 0 and 16 years at the time of enrollment. * Males with suspected Central Precocious Puberty (CPP), defined by a testicular volume โ‰ฅ4 mL before 9 years of age. * Females with suspected CPP, defined by the onset of thelarche before 8 years of age. * Males with suspected Delayed Puberty (DP), defined by testicular volume \<4 mL by 14 years of age. * Females with suspected DP, defined by the absence of thelarche by 13 years of age. * Written informed consent for study participation and personal data processing provided by the parents/legal guardians, with the assent of the participating minor. Exclusion Criteria: * Presence of congenital or acquired conditions known to primarily alter pubertal development or gonadal function, regardless of HPG axis physiology (e.g., disorders of sex development, anorchia, previous ovariectomy, uncorrected bilateral cryptorchidism, previous iatrogenic gonadotoxicity). * Primary endocrine diseases interfering with hypothalamic-pituitary-gonadal axis regulation (e.g., congenital hypogonadotropic hypogonadism, panhypopituitarism). * Use of hormonal therapies or drugs capable of modifying gonadal function or the response to the GnRH test (e.g., exogenous sex steroids, androgens/anabolic steroids).
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Bologna 40138
Bologna, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy